Terran Jamie, McHugh Brian J, Fischer Charla R, Lonner Baron, Warren Daniel, Glassman Steven, Bridwell Keith, Schwab Frank, Lafage Virginie
Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, New York, NY.
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT.
Ochsner J. 2014 Spring;14(1):14-22.
In the United States, expenditures related to spine care are estimated to account for $86 billion annually. Policy makers have set a cost-effectiveness benchmark of less than $100,000/quality adjusted life year (QALY), forcing surgeons to defend their choices economically. This study projects the cost/QALY for surgical treatment of adult spinal deformity at 5-year follow-up based on 2-year cost- and health-related quality-of-life (HRQOL) data.
In a review of 541 patients with adult spinal deformity, the patients who underwent revision or were likely to undergo revision were identified and cost of surgery was doubled to account for the second procedure; all other patients maintained the cost of the initial surgery. Oswestry Disability Index (ODI) was modeled by revision status based on literature findings. Total surgical cost was based on Medicare reimbursement. Chi square and student t tests were utilized to compare cost-effective and non-cost-effective patients.
The average cost/QALY at 5-year follow-up was $120,311.73. A total of 40.7% of patients fell under the threshold of a cost/QALY <$100,000. Cost-effective patients had higher baseline ODI scores (45% vs 34% [P=0.001]), lower baseline total Scoliosis Research Society scores (2.89 vs 3.00 [P=0.04]), and shorter fusions (8.23 vs 9.87 [P=0.0001]).
We found 40.7% of patients to be below the threshold of cost effectiveness. Factors associated with reaching the threshold <$100,000/QALY were greater preoperative disability, diagnosis of idiopathic scoliosis, poor preoperative HRQOL scores, and fewer fusion levels.
在美国,每年与脊柱护理相关的支出估计达860亿美元。政策制定者设定了低于10万美元/质量调整生命年(QALY)的成本效益基准,这迫使外科医生从经济角度为自己的选择进行辩护。本研究基于2年的成本和健康相关生活质量(HRQOL)数据,预测了成人脊柱畸形手术治疗在5年随访时的成本/QALY。
在对541例成人脊柱畸形患者的回顾中,识别出接受翻修手术或可能接受翻修手术的患者,并将手术成本加倍以计入第二次手术;所有其他患者维持初次手术的成本。根据文献研究结果,按翻修状态对Oswestry功能障碍指数(ODI)进行建模。手术总成本基于医疗保险报销。采用卡方检验和学生t检验比较成本效益高和成本效益低的患者。
5年随访时的平均成本/QALY为120311.73美元。共有40.7%的患者低于成本/QALY<10万美元的阈值。成本效益高的患者基线ODI评分较高(45%对34%[P=0.001]),基线脊柱侧凸研究学会总分较低(2.89对3.00[P=0.04]),融合节段较短(8.23对9.87[P=0.0001])。
我们发现40.7%的患者低于成本效益阈值。达到<10万美元/QALY阈值的相关因素包括术前残疾程度更高、特发性脊柱侧凸诊断、术前HRQOL评分较差以及融合节段较少。